JP MORGAN/CALL/BOSTON SCIENTIFIC/70/0.1/15.11.24 Share Price

Warrant

DE000JK45TX2

Real-time Bid/Ask 15:11:27 02/07/2024 BST
1.01 EUR / 1.02 EUR -7.73% Intraday chart for JP MORGAN/CALL/BOSTON SCIENTIFIC/70/0.1/15.11.24
1 month+5.77%
3 months+37.50%
Date Price Change
02/07/24 1.04 -5.45%
01/07/24 1.1 0.00%
28/06/24 1.1 +0.92%
27/06/24 1.09 -6.03%
26/06/24 1.16 +5.45%

Delayed Quote Börse Stuttgart

Last update July 02, 2024 at 07:43 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying BOSTON SCIENTIFIC CORPORATION
Issuer J.P. Morgan
WKN JK45TX
ISINDE000JK45TX2
Date issued 19/03/2024
Strike 70 $
Maturity 15/11/2024 (136 Days)
Parity 10 : 1
Emission price 0.43
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.19
Lowest since issue 0.71
Delta0.72x
Omega 4.958
Premium6.39x
Gearing6.92x
Moneyness 1.088
Difference Strike -5.985 $
Difference Strike %-8.55%
Spread 0.01
Spread %0.97%
Theoretical value 1.025
Implied Volatility 37.29 %
Total Loss Probability 36.55 %
Intrinsic value 0.5715
Present value 0.4535
Break even 80.99 €
Theta-0.02x
Vega0.01x
Rho0.02x

Company Profile

Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows: - cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%); - endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ; - neuromodulation (2%). The United States account for 59.2% of net sales.
Sector
-
More about the company

Ratings for Boston Scientific Corporation

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Boston Scientific Corporation

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
76.41 USD
Average target price
82.35 USD
Spread / Average Target
+7.78%
Consensus